DPP-4 inhibitors have become standard drugs to improve hemoglobin A1c (HbA1c) levels in patients with diabetes, though improvement of cardiovascular outcomes by adding DPP-4 inhibitors to usual care in diabetic patients with established cardiovascular diseases has not yet been shown [6–8]. The gene discussed is DPP4; the disease is diabetes mellitus.